InsiderTrades

Form 4 for AVBP ArriVent BioPharma, Inc.

Accepted 2025-07-15 00:00:00 ET · period of report 2025-07-11 · accession 0001104659-25-067928 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-07-15 2025-07-11 AVBP LaChapelle Robin COO M - OptEx $2.28 +11.2K 129.2K +9% +$25.4K
DM 2025-07-15 2025-07-11 AVBP LaChapelle Robin COO M - OptEx $0.00 -11.2K 410 -96% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-07-11 M A 2,050 $2.28 126,633 D — —
2 Common Common Stock 2025-07-11 M A 6,503 $2.28 135,736 D — —
3 Common Common Stock 2025-07-11 M A 2,600 $2.28 129,233 D — —
4 Derivative Stock Option (right to buy) 2025-07-11 M D 2,600 $0.00 12,873 D $2.28 · — to 2032-01-31 2,600 Common Stock (F3) The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
5 Derivative Stock Option (right to buy) 2025-07-11 M D 6,503 $0.00 6,370 D $2.28 · — to 2032-01-31 6,503 Common Stock (F3) The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
6 Derivative Stock Option (right to buy) 2025-07-11 M D 2,050 $0.00 410 D $2.28 · — to 2031-09-07 2,050 Common Stock (F2) The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.